<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" dms-id="H2FA59188B0FF48A19F80267CD42C7767" public-private="public" key="H" bill-type="olc"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>118 HR 6664 IH: Innovation in Pediatric Drugs Act of 2023</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2023-12-07</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">I</distribution-code><congress display="yes">118th CONGRESS</congress><session display="yes">1st Session</session><legis-num display="yes">H. R. 6664</legis-num><current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber><action display="yes"><action-date date="20231207">December 7, 2023</action-date><action-desc><sponsor name-id="E000215">Ms. Eshoo</sponsor> (for herself and <cosponsor name-id="M001157">Mr. McCaul</cosponsor>) introduced the following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name></action-desc></action><legis-type>A BILL</legis-type><official-title display="yes">To encourage innovation in the development of pediatric drugs, and for other purposes.</official-title></form><legis-body id="HC6C668ECC8D342F0A9BADCDFFF63B4AB" style="OLC"> 
<section id="H01338E2A71AC41F286CF2A8D9E7DAFF1" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Innovation in Pediatric Drugs Act of 2023</short-title></quote>. </text></section> <section id="HD11905C3409C40D788D843B1F874A11B"><enum>2.</enum><header>Pediatric studies of orphan drugs</header> <subsection id="H50AAC554D3A8498EA97BD002BFC5F9E3"><enum>(a)</enum><header>Application of pediatric research requirements to orphan drugs</header> <paragraph id="HE94F2C22EE104D4FAB62431052614903"><enum>(1)</enum><header>In general</header><text>Section 505B of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355c">21 U.S.C. 355c</external-xref>) is amended by striking subsection (k).</text></paragraph> 
<paragraph id="HDCACCEF70D52416488E987A28E332459"><enum>(2)</enum><header>Applicability</header><text>The amendment made by paragraph (1) applies only to applications described in subparagraph (A) or (B) of section 505B(a)(1) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355c">21 U.S.C. 355c(a)(1)</external-xref>) that are submitted on or after the date that is 18 months after the date of enactment of this Act.</text></paragraph></subsection> <subsection id="HB839820817534A75B911FD2B70E7F7E2"><enum>(b)</enum><header>Guidance</header><text display-inline="yes-display-inline">The Secretary of Health and Human Services (referred to in this Act as the <quote>Secretary</quote>) shall—</text> 
<paragraph id="HD53EF8938C014282931832CB404D97C8"><enum>(1)</enum><text display-inline="yes-display-inline">not later than 6 months after the date of enactment of this Act, issue draft guidance describing how, upon the applicability of the amendment made by subsection (a)(1), the requirements of section 505B of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355c">21 U.S.C. 355c</external-xref>) will apply with respect to any drug or biological product for an indication for which orphan designation has been granted under section 526 of such Act (<external-xref legal-doc="usc" parsable-cite="usc/21/360bb">21 U.S.C. 360bb</external-xref>); and</text></paragraph> <paragraph id="H471A9495CCA24FD7B37F7AB6B363C247"><enum>(2)</enum><text>not later than 18 months after the date of enactment of this Act, finalize such draft guidance.</text></paragraph></subsection> 
<subsection id="HEDECC45636A04A5EB8D37221FBE237AF"><enum>(c)</enum><header>Content of guidance</header><text>The guidance under subsection (b) shall address the following:</text> <paragraph id="HD1C05A664BE745A1BE385E94805F54CB"><enum>(1)</enum><text display-inline="yes-display-inline">Information regarding how full and partial waivers under subsections (a)(5)(A), (a)(5)(B), and (b)(2) of section 505B of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355c">21 U.S.C. 355c</external-xref>) for any drug or biological product for an indication for which orphan designation has been granted under section 526 of such Act (<external-xref legal-doc="usc" parsable-cite="usc/21/360bb">21 U.S.C. 360bb</external-xref>) will be granted (including a description of impossible or highly impracticable studies for indications for which orphan designation has been granted under such section 526).</text></paragraph> 
<paragraph id="HC9FF4A3CAB5F4AA399C084F715FC617A"><enum>(2)</enum><text display-inline="yes-display-inline">Application of the requirements of section 505B(e) of such Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355c">21 U.S.C. 355c(e)</external-xref>) to drugs or biological products for an indication for which orphan designation has been granted under section 526 of such Act (<external-xref legal-doc="usc" parsable-cite="usc/21/360bb">21 U.S.C. 360bb</external-xref>), including submission and timing of planned requests for full or partial waivers and responses by the Food and Drug Administration to those requests.</text></paragraph> <paragraph id="H40653198E2A64534A0944DE0C50988A8"><enum>(3)</enum><text display-inline="yes-display-inline">Process for regularly updating conditions that automatically qualify for a waiver under subsection (a)(5)(A) or (b)(2)(A) of section 505B of such Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355c">21 U.S.C. 355c</external-xref>).</text></paragraph> 
<paragraph id="HA69C48DF0D9B46C4AADFED6F8D7CD439"><enum>(4)</enum><text display-inline="yes-display-inline">Situations where the initial pediatric study plan under section 505B(e) of such Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355c">21 U.S.C. 355c(e)</external-xref>) includes a plan to study the drug or biological product in all relevant pediatric age groups.</text></paragraph> <paragraph id="HE893DFBE95D44A0D9DE61C0ECCA919B0"><enum>(5)</enum><text display-inline="yes-display-inline">Consideration of how the Secretary of Health and Human Services will balance the unique scientific challenges of rare disease drug development with the need for improved pediatric labeling of drugs and biological products for indications for which orphan designation has been granted under section 526 of such Act (<external-xref legal-doc="usc" parsable-cite="usc/21/360bb">21 U.S.C. 360bb</external-xref>).</text></paragraph> 
<paragraph id="H46BF93D85E29473E833CC41570334DF7"><enum>(6)</enum><text display-inline="yes-display-inline">Applicability of real-world evidence in the fulfillment of requirements under section 505B of such Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355c">21 U.S.C. 355c</external-xref>).</text></paragraph> <paragraph id="H1B528E95D05C40738780C9162E892C7B"><enum>(7)</enum><text>Consideration of input received from the public meeting set forth in subsection (d).</text></paragraph></subsection> 
<subsection id="H10F7C4239AD44362A82B4EF42ECB7E39"><enum>(d)</enum><header>Public meeting</header><text>The Secretary shall—</text> <paragraph id="HC220EF623C474C0CADF01FE0D8E06BA7"><enum>(1)</enum><text display-inline="yes-display-inline">not later than 1 year after the date of enactment of this Act, hold a public meeting to inform the final guidance to be issued under subsection (b)(2); and</text></paragraph> 
<paragraph id="H0F28385B843840DC94215836B18EF764"><enum>(2)</enum><text>publish prior notice of such meeting in the Federal Register.</text></paragraph></subsection> <subsection id="HF4D19CD80EC04A83971C2957198CF6F3"><enum>(e)</enum><header>GAO study</header><text display-inline="yes-display-inline">Not later than 4 years after the date of enactment of this Act, the Comptroller General of the United States shall submit to the Committee on Energy and Commerce and the Committee on Ways and Means of the House of Representatives and the Committee on Health, Education, Labor, and Pensions of the Senate a report that—</text> 
<paragraph id="H1CAA2CBD57184EACA5EDA21D236D43F3"><enum>(1)</enum><text>addresses the impacts of this Act on—</text> <subparagraph id="H43B316BEB30F4AA2839B7B9CAE87149E"><enum>(A)</enum><text>rare disease drug development in the United States; and</text></subparagraph> 
<subparagraph id="HA7F82C32A324441791DA47CAC9395A8C"><enum>(B)</enum><text>the increased availability of pediatric information on drugs and biological products for indications for which orphan designation has been granted under section 526 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/360bb">21 U.S.C. 360bb</external-xref>); and</text></subparagraph></paragraph> <paragraph id="H04916110A63C43039D50C8705CD89528"><enum>(2)</enum><text>includes—</text> 
<subparagraph id="HA7205EC7740347119024C5DDE0689832"><enum>(A)</enum><text>the findings of a survey of companies of varying sizes engaged in the development of orphan drugs; and</text></subparagraph> <subparagraph id="H480C04AB62C74345B7F2E1269CDD050E"><enum>(B)</enum><text>input from patient groups and medical provider associations.</text></subparagraph></paragraph></subsection> 
<subsection id="HF07CED117B7A4DC58FE341940450B0AD"><enum>(f)</enum><header>Rule of construction</header><text display-inline="yes-display-inline">Nothing in this section shall be construed to limit requirements for investigations, as described in section 505B(a)(3) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355c">21 U.S.C. 355c(a)(3)</external-xref>), of molecularly targeted pediatric cancer drugs for which orphan designation has been granted under section 526 of such Act (<external-xref legal-doc="usc" parsable-cite="usc/21/360bb">21 U.S.C. 360bb</external-xref>).</text></subsection></section> <section id="HDB7ABD1F6FFE4A9BA275872FE998B938"><enum>3.</enum><header>Reauthorizing the program for pediatric studies of drugs</header><text display-inline="no-display-inline">Section 409I(d)(1) of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/284m">42 U.S.C. 284m(d)(1)</external-xref>) is amended in paragraph (1) by striking <quote>$25,000,000 for each of fiscal years 2023 through 2027</quote> and inserting <quote>$50,000,000 for each of fiscal years 2023 through 2027</quote>.</text></section> 
<section id="HC7953F50702A46A380B668E34873887D"><enum>4.</enum><header>Ensuring completion of pediatric study requirements</header> 
<subsection id="H1BEB789AB433410D997E5931D3662792"><enum>(a)</enum><header>Equal accountability for pediatric study requirements</header><text>Section 505B(d)(2) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355c">21 U.S.C. 355c(d)(2)</external-xref>) is amended by striking <quote>(except that the drug or biological product shall not be subject to action under section 303)</quote>.</text></subsection> <subsection id="HBE4D30915F554A79865C185F27014442"><enum>(b)</enum><header>Conforming amendments</header><text>Section 303(f)(4)(A) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/333">21 U.S.C. 333(f)(4)(A)</external-xref>) is amended by striking <quote>or 505–1</quote> and inserting <quote>505–1, or 505B</quote>.</text></subsection> 
<subsection id="H08B1468538394D038A09504D8B0D3D8D"><enum>(c)</enum><header>Transition rule</header><text display-inline="yes-display-inline">The Secretary of Health and Human Services shall take no enforcement actions under section 303 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/333">21 U.S.C. 333</external-xref>) for failures described in section 505B(d) of such Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355c">21 U.S.C. 355c(d)</external-xref>) before the date this is 180 days after the date of enactment of this Act.</text></subsection></section> <section id="HC06EB2843EDB40699F618DCB55DC88C4"><enum>5.</enum><header>FDA report on PREA enforcement</header><text display-inline="no-display-inline">Section 508(b) of the Food and Drug Administration Safety and Innovation Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355c-1">21 U.S.C. 355c–1(b)</external-xref>) is amended—</text> 
<paragraph id="H496E0F19EA2E44C1BC256D56B8B964DB"><enum>(1)</enum><text display-inline="yes-display-inline">in paragraph (11), by striking the semicolon at the end and inserting <quote>, including an assessment of the appropriateness of deferrals and deferral extensions granted for such products and an evaluation of compliance with deadlines provided for in such deferrals and deferral extensions;</quote>; </text></paragraph> <paragraph id="H08120370AFFC4B858DC52CD350119FA2"><enum>(2)</enum><text>in paragraph (15), by striking <quote>and</quote> at the end;</text></paragraph> 
<paragraph id="H3E5B52B0C3A04E40AF4FDB76E5F2621D"><enum>(3)</enum><text>in paragraph (16), by striking the period at the end and inserting <quote>; and</quote>; and</text></paragraph> <paragraph id="HC6FB7890BC6943E6BEDE989E7613C1A8"><enum>(4)</enum><text>by adding at the end the following:</text> 
<quoted-block style="OLC" id="H1F84ABB93AD840A7A96E4883D670ED81" display-inline="no-display-inline"> 
<paragraph id="HCD33760E88E844CB92D5E0FE3ED0C7DB"><enum>(17)</enum><text display-inline="yes-display-inline">a listing of penalties, settlements, or payments under section 303 of the Federal Food, Drug, and Cosmetic Act for failure to comply with requirements under section 505B of such Act, including for each penalty, settlement, or payment the name of the drug, the sponsor thereof, and the amount of the penalty, settlement, or payment imposed.</text></paragraph><after-quoted-block>.</after-quoted-block></quoted-block></paragraph></section> </legis-body></bill>

